MBX Biosciences is projected to report no revenue and a consensus loss of $0.63 per share for Q2 2026, with the current $69.52 share price trading below the $80.40 average analyst target. The key story for this report is the clinical progress of canvuparatide (MBX-2109), specifically the upcoming initiation of Phase 3 trials for chronic hypoparathyroidism.
The company’s stock recently reached all-time highs following positive interim results for its obesity candidate, MBX-4291, which demonstrated competitive weight loss data in early-stage trials. Analysts are also watching for updates on the company’s cash runway, which was previously estimated to fund operations through 2029.